secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001785530-25-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025
--------------------------------------------------------------------------------

- Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.
- Net loss of $16.4M for Q3 2025, comparable to $16.7M in Q3 2024; R&D expense $11.6M, G&A $4.1M.
- WTX-124 received Fast Track Designation; interim Phase 1/1b data and End of Phase 1 FDA meeting expected in Q4 2025.
- WTX-330 Phase 1b/2 update and development plan expected in Q4 2025.
- WTX-1011 (anti-STEAP1 T-cell engager) in IND-enabling studies; target candidate nomination planned by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/0001785530-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/howl-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001785530-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer